Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel

NCT06538272 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

CIPN - Chemotherapy-Induced Peripheral Neuropathy

Interventions

DRUG: ONO-2910
DRUG: Placebo

Sponsor

Ono Pharmaceutical Co., Ltd.